Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 6Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 6Breast Neoplasms 5Sarcoma 3Ovarian Cancer Recurrent 3Carcinoma, Ovarian Epithelial 3Sarcoma, Ewing 2Neoplasm Metastasis 2Leiomyosarcoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Low Grade Serous Ovarian Cancer 1Liposarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1HER2-negative Breast Cancer 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Dermatofibrosarcoma 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × liposomal doxorubicin × Clear all
NCT07213804 2026-05-27

FRAmework-01

Eli Lilly and Company

Phase 3 Recruiting
1,080 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡